Letter from the Editor: Evidentiary standards may be entering a much-needed new era

ARTICLE | Product Development

A series of articles showcases innovation in tools and standards for generating evidence to support new therapies

By C. Simone Fishburn, Editor in Chief 

November 4, 2023 12:52 AM UTC

All CEOs, all heads of R&D, all drug developers center their strategies around the central question: what is the level of evidence we need to get our therapy approved?

While the question has been around for as long as the industry, the answer is continually changing.